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Summary 14 
KSHV seroprevalence is very high in rural Uganda. Malaria infection and anaemia are the risk factors 15 
associated with KSHV seroprevalence and antibody levels in this study. These factors might cause 16 
reactivation of the virus and hence lead to increased transmission. 17 
 18 
Abstract 19 
We examined anaemia and malaria as risk factors for KSHV seropositivity and antibody levels in a 20 
long-standing rural Ugandan cohort, in which KSHV is prevalent. Samples from 4134 children, aged 21 
1-17 years, with a sex ratio of 1:1 and 3149 adults aged 18-103 years, 41% of whom were males, 22 
were analysed. Among children, malaria infection was associated with higher KSHV prevalence (61% 23 
versus 41% prevalence among malaria infected and uninfected respectively); malaria was not 24 
assessed in adults. Additionally, lower haemoglobin level was associated with an increased 25 
prevalence of KSHV seropositivity, both in children and in adults.  26 
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Introduction  29 
We recently reported KSHV prevalence of 95% among adults in a rural population cohort (the 30 
General Population Cohort (GPC) in Uganda [1], the highest prevalence of KSHV ever reported, in 31 
addition to high KSHV antibody levels. We propose that the very high prevalence in this population 32 
may be driven by frequent KSHV reactivation, viral shedding and transmission rates and that the 33 
high antibody levels also reflect frequent reactivation. It is important therefore to study potential co-34 
factors for reactivation in relation to KSHV prevalence and antibody levels. We have previously 35 
reported an association between malaria and hookworm infections and KSHV seropositivity in an 36 
urban population in Uganda [2, 3]. Since both malaria and hookworm are associated with anaemia, 37 
we hypothesized that anaemia may have a role in KSHV transmission via viral reactivation. This 38 
hypothesis is supported by data from in vitro experiments showing reactivation of KSHV in 39 
conditions of hypoxia [4]. In this study we aimed to confirm the high prevalence of KSHV in the GPC 40 
in recent years, with higher ART coverage, and determine the role of anaemia and malaria co-41 
infection as risk factors for KSHV prevalence and antibody levels in a highly endemic population.  42 
 43 
Methods 44 
Study population and socio-demographic data collection 45 
The General Population Cohort (GPC) is located in south-western Uganda in Kyamulibwa sub-46 
community of Kalungu district with an altitude of approximately 1200m above sea level. It is 47 
community-based open cohort of about 22,000 people in 25 adjacent villages [5]. This cross 48 
sectional study analysed plasma samples collected from two surveys, the adult survey and the 49 
children survey. The adults were surveyed in 2014/2015 and the children in 2016. Adults without 50 
haematological parameter data and children without either haematological parameter data or 51 
malaria parasitaemia status data were excluded in the laboratory analysis. Children less than 1 year 52 
of age were excluded from the statistical analysis and children less than 2 years were not tested for 53 
HIV serostatus, due to the potential for maternal IgG to be present, which could affect antibody 54 
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measurement. Socio-economic scores were generated for adults using Principal Component Analysis 55 
of various household indicators during the previous survey. 56 
 57 
Ethical approval 58 
The study was approved by the Research and Ethics Committee Uganda Virus Research Institute and 59 
the Uganda National Council for Science and Technology.  60 
 61 
Haematological and serological analysis 62 
During these two surveys, blood was collected from study participants and tested immediately after 63 
collection for HIV; a smaller proportion of samples were also tested for malaria parasitaemia and 64 
haemoglobin levels, using point-of care assays and rapid tests. HIV serostatus was determined using 65 
rapid diagnostic tests. Malaria parasitaemia was measured in children only, using malaria Rapid 66 
Diagnostic Tests (ONE STEP Malaria HRP-II (P.f) and pLDH (Pan) Antigen Rapid Test). Haemoglobin 67 
levels in g/dL were obtained from the Haemocue 201 analyzer.  68 
 69 
Stored plasma samples for both children and adults were retrieved and tested for KSHV antibodies 70 
using an in-house ELISA as previously described [6].  Samples from the two surveys were tested 71 
separately after simple randomisation onto ELISA plates. Antibodies to both K8.1 and ORF73 72 
proteins were measured as optical density. Each ELISA plate contained three negative and positive 73 
control wells; negative controls were used to calculate a cut-off value for every plate as previously 74 
described [2, 7]. Seropositivity was defined as reactivity to either K8.1 or ORF73 proteins. 75 
 76 
Statistical analysis 77 
Statistical analysis was carried out using STATA13 (Statacorp, College Station, Texas USA). Children’s 78 
and adults’ results were analysed separately. Haemoglobin levels were mean centred for easier 79 
interpretation. Anaemia was defined using haemoglobin levels in g/dL after altitude adjustment 80 
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following WHO guidelines [8]. A constant value 0.5 was subtracted from haemoglobin levels for 81 
altitude adjustment, the results were then categorised into normal and anaemic using the following 82 
cut-off values: 11.0 for pregnant females and children below 5 years, 11.5 for children 5 to 11 years, 83 
12.0 for children 12 to 14 years and other females 15 years and above, 13.0 for males 15 years and 84 
above. These WHO haemoglobin reference ranges used to define anaemia may not be 85 
representative of African populations, as previously reported [9, 10], because they are based on 86 
western population data. We therefore analysed haemoglobin both as a continuous variable and as 87 
categorised into normal and anaemic using separate regression models. 88 
 89 
Linear regression with bootstrapped confidence intervals was used for antibody levels analysis, 90 
because they were severely skewed. Logistic regression was used for seroprevalence analysis, 91 
furthermore, we adjusted for clustering at the village level using survey commands. We assessed 92 
interaction between age and haemoglobin levels, as well as between age and anaemia in relation to 93 
anti-K8.1 antibody levels, anti-ORF73 antibody levels and KSHV prevalence based on a priori 94 
suspicions of interaction, using likelihood ratio tests.  95 
 96 
Results 97 
The characteristics of the individuals analysed are shown in supplementary Table 1. We analysed 98 
results from 3149 adults and 4134 children.  This analysis included children aged 1 to 17 years and 99 
adults aged 18 to 103 years (supplementary Table 1).  100 
 101 
Risk factors for KSHV prevalence and antibody levels among adults  102 
KSHV prevalence was 91% in all adults (2871/3149) (supplementary Figure 1). Every 1g/dL decrease 103 
in haemoglobin values was associated with increased odds of being KSHV seropositive (OR=0.86 104 
(0.77, 0.96), P=0.006 and anaemic individuals were more likely to be KSHV seropositive compared to 105 
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people with normal haemoglobin values, but this association was not statistically significant OR=1.25 106 
(0.87, 1.79), P=0.229 (Table 1A).  107 
 108 
We then analysed antibody levels to K8.1 and ORF73 proteins as continuous variables without 109 
categorising participants as seropositive or seronegative.  Anaemic adults had higher antibodies to 110 
ORF73 protein compared to individuals with normal haemoglobin values (coef. 0.28 (0.16, 0.39), 111 
P<0.0001. Similarly, every 1g/dL decrease in haemoglobin was associated with an increase in ORF73 112 
antibody ODs (Table 1B). The association between haemoglobin and antibodies to ORF73 protein 113 
was strongest among older people (Table 1C). Conversely, anti-K8.1 antibody levels were not 114 
significantly associated with either haemoglobin levels or anaemia (Table 1B). This might be 115 
attributed to the relative abundance of LANA compared to late lytic proteins such as K8.1, even 116 
during KS disease [11].   117 
 118 
Compared to HIV negative adults, HIV positive adults had lower antibodies to KSHV, especially those 119 
with CD4 counts of 500cell/L or less (Table 1B). This may be due to B cell dysfunction caused by HIV 120 
infection, and consequent decreased antibody responses [12, 13]. On the other hand, HIV positive 121 
adults with CD4 counts above 500cells/L, compared to HIV negative adults were more likely to be 122 
KSHV seropositive (Table 1A), which may be due to antiretroviral treatment. 123 
 124 
Risk factors for KSHV prevalence and antibody levels among children 125 
We then investigated associations between KSHV prevalence and antibody levels and risk factors 126 
among children. Overall, KSHV prevalence was 51% (2117/4134) in the children, the prevalence 127 
increased with age, rising from 31% among 1-5 year olds, to 53% among 6-12 year olds, to 73% 128 
among 13-17 year olds (supplementary Figure 1). We first adjusted for HIV status, age and sex, then 129 
malaria parasitaemia and anaemia/haemoglobin levels were added in the full models. In the first 130 
analysis, haemoglobin levels, malaria parasitaemia and age were strongly associated with KSHV 131 
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prevalence (Table 2A). Every 1 g/dL decrease in haemoglobin levels increased the odds of being 132 
KSHV seropositive by 11% (P<0.0001) and the odds of being KSHV positive if anaemic compared to 133 
with normal haemoglobin levels was 1.42 (1.18, 1.71) (p<0.0001). The odds of being KSHV 134 
seropositive, if malaria infected, compared to the uninfected were 2.26 (1.85, 2.77) (P<0.0001) and 135 
every annual increase in age was associated with a 17% increased risk of being KSHV seropositive 136 
(Table 2A).  137 
 138 
After adjusting for malaria parasitaemia, the risk of being KSHV seropositive for every 1 g/dL 139 
decrease in haemoglobin reduced to 7% (p=0.005). Similarly, the odds of being KSHV seropositive in 140 
comparing anaemic individuals to people with normal haemoglobin levels reduced to 1.23 (1.01, 141 
1.49) p=0.037.  After adjusting for haemoglobin levels, the odds of being KSHV seropositive 142 
comparing people with and without malaria parasitaemia changed little (OR=2.12 (1.75, 2.57), 143 
p<0.0001) (Table 2A). Every annual increase in age remained strongly associated with increased 144 
KSHV prevalence risk, OR=1.18 (P<0.0001) even after adjusting for malaria parasitaemia and 145 
haemoglobin (Table 2A). 146 
 147 
We then finally investigated associations between the same risk factors and KSHV antibody levels 148 
(OD) as continuous variables without categorising participants as seropositive or seronegative. Only 149 
malaria parasitaemia was associated with both anti-K8.1 and anti-ORF73 antibody levels in the fully 150 
multivariate analysis (Table 2B).  151 
 152 
Discussion  153 
We observed a significant association between haemoglobin levels and KSHV prevalence among 154 
children and adults, where people with low levels of haemoglobin were more likely to be KSHV 155 
seropositive. As a categorical variable, anaemia was associated with KSHV prevalence among 156 
children. Reduction in haemoglobin has been shown to cause hypoxia/low tissue oxygen, while 157 
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hypoxia has been shown to reactivate KSHV in-vitro [4]. We therefore hypothesise that low 158 
haemoglobin levels leads to reactivation of KSHV through hypoxia. Increased reactivation may help 159 
spread the virus during initial infection. Alternately, hypoxia may enhance initial infection of cells, 160 
possibly through upregulation of the replication and transcription activator [14]. In this cross 161 
sectional study, we did not directly measure KSHV reactivation or KSHV viral load in blood or plasma, 162 
although antibody levels may be viewed as a surrogate marker for frequent reactivation. The 163 
connection between KSHV reactivation, hypoxia and anaemia requires further investigation.  164 
 165 
We showed that children infected with malaria are more likely to be KSHV seropositive. Additionally, 166 
the effect of anaemia and/or haemoglobin levels on KSHV prevalence and antibody levels reduced to 167 
about 50% after adjusting for malaria infection. Malaria causes anaemia, and in part the anaemia 168 
effect in children could be explained (confounded) by malaria infection. The consistent association 169 
between malaria infection and KSHV prevalence suggests malaria may be driving KSHV transmission 170 
in malaria endemic areas. This might imply that exposure to malaria significantly impacts on KSHV 171 
reactivation, which might also have long lasting effects. The mechanism through which malaria may 172 
reactivate KSHV requires further investigation.  173 
 174 
Conclusion  175 
Findings from this study suggest malaria infection as a risk factor for KSHV prevalence. Malaria 176 
associated anaemia is one mechanism that likely contributes to this association but cannot entirely 177 
explain it. In KSHV and malaria endemic areas, a number of other parasite co-infections such as 178 
helminths, which cause anaemia and/or immunomodulation are common. The role of multiple 179 
parasitic infections and KSHV transmission and pathogenesis warrants further careful study.  180 
 181 
 182 
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Supplementary Figure 1 title: KSHV prevalence and 95% confidence intervals across ages 1 to 103 224 
years among individuals from the General Population Cohort in south-western Uganda 225 
Supplementary Figure 1 legend: KSHV seroprevalence defined as antibody reactivity to either K8.1 or 226 
ORF73 antigens. Anti-K8.1 and anti-ORF antibodies detected using ELISA. 227 
  228 
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